Cogent Biosciences, Inc. Fair Value of Long-Term Debt
Cogent Biosciences, Inc. (COGT) had Fair Value of Long-Term Debt of $281.30 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2026-08-10
- 2026-06-30: Long-term Debt, Fair Value $281.30M.
- 2026-03-31: Long-term Debt, Fair Value $281.00M.
- 2025-12-31: Long-term Debt, Fair Value $270.30M.
| Period end | Long-term Debt, Fair Value |
|---|---|
| 2026-06-30 | $281.30M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $281.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $270.30M 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |